Search bioRxiv⌕ Search

Biology subjects

Wong, A. S.-T.

Publications and source records attributed to Wong, A. S.-T..

3 recordsLinked to original sources

PCRD-seq: Proximity Crosslinking-induced RNA Depletion for Low-Input Subcellular Transcriptome Profiling

Chromatin-associated RNAs play critical roles in regulating chromatin organization and transcription, underscoring the importance of their study. Proximity labeling has emerged as a promising and versatile technique for profiling chromatin-associated RNAs with high spatiotemporal resolution. While being a powerful technique, traditional proximity labeling methods depend on complex, high-input enrichment protocols, which significantly limit their wide practical application. Here, we developed a straightforward, enrichment-free chromatin-associated RNA profiling strategy: Proximity Crosslinking-induced RNA Depletion sequencing (PCRD-seq). This approach leverages the proximity crosslinking between chromatin and its surrounding RNAs induced by singlet oxygen generated by HoeDBF, a photosensitizer targeting chromatin region. The proximity crosslinking hinders the release of chromatin-associated RNAs during routine TRIzol extraction, consequently leading to a specific depletion of these RNAs. This method was successfully applied to investigate the role of U1 snRNA in RNA chromatin retention and the differences in chromatin-associated transcriptomes between two ovarian cancer cell lines with opposite metastatic capability. Moreover, our PCRD-seq exhibits potential in profiling nuclear lamina-associated RNAs, which paves the way for its application to profile RNAs associated with other chromatin subdomains. The minimal cell input and simple workflow endow PCRD-seq as a transformative tool for wide applications.

cell biology↗

Cancer-specific sialylation of insulin-like growth factor 1 receptor impairs therapeutic antibody binding and efficacy

Despite extensive efforts to develop insulin-like growth factor (IGF1R)-targeted therapies for various malignancies, none has received clinical approval in the past two decades. Here, we reveal that N-glycan sialylation significantly decreases recognition by the humanized monoclonal anti-IGF1R antibody ganitumab across various cancer types, reducing its efficacy both in vitro and in vivo. Sialoforms of IGF1R are virtually absent in normal cells, indicating that the modification is tumor-specific. Pharmacological inhibition of sialyltransferases significantly sensitizes metastatic tumors to ganitumab in a ganitumab-resistant ovarian cancer model. Enzymatic removal of sialic acids from tissue sections resulted in marked enhancement in antibody binding to ovarian cancer patient tumors, but not normal tissues. Upregulation of 2-6 sialyltransferase ST6GAL1 in tumor tissues was found to be responsible for sialylation of IGF1R. Consequently, ST6GAL1-high tumors were more likely to benefit from desialylation-mediated enhancement of ganitumab binding. Furthermore, through comprehensive glycoproteomics analysis, structural prediction, and molecular dynamics simulation, we identify Asn-607 (N607) as a crucial site harboring sialylated glycans. Mechanistically, N607 glycosylation destabilizes the IGF1R-ganitumab complex. Overexpression of IGF1R Asn-607-Gln (N607Q) mutant in IGF1R-knockout cancer cells increases ganitumab efficacy compared to wild-type IGF1R in vivo. Taken together, these findings highlight sialylation as a common barrier in IGF1R-targeted therapies and provide crucial insights for therapy enhancement in cancer and patient stratification for future clinical trials. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=99 SRC="FIGDIR/small/682592v1_ufig1.gif" ALT="Figure 1"> View larger version (14K): org.highwire.dtl.DTLVardef@17c6d5corg.highwire.dtl.DTLVardef@1efe2f7org.highwire.dtl.DTLVardef@1dd05aorg.highwire.dtl.DTLVardef@159fb23_HPS_FORMAT_FIGEXP M_FIG C_FIG Synopsis2-6 sialylation of IGF1R Asn-607 by ST6GAL1 is prevalent in cancer. This modification disrupts the interaction of IGF1R with therapeutic mAb ganitumab. Removal of sialylation augments ganitumab efficacy.

cancer biology↗

Bola-amphiphilic dendrimer empowers imatinib to target metastatic ovarian cancer stem cells via beta-catenin-HRP2 signaling axis

Ovarian cancer is the leading cause of death among all gynecological malignancies, and drug resistance renders the current chemotherapy agents ineffective for patients with advanced metastatic tumors. We report an effective treatment strategy for targeting metastatic ovarian cancer involving a nanoformulation (Bola/IM) - bola-amphiphilic dendrimer (Bola)-encapsulated imatinib (IM) - to target the critical mediator of ovarian cancer stem cells (CSCs) CD117 (c-Kit). Bola/IM offered significantly more effective targeting of CSCs compared to IM alone, through a novel and tumor-specific {beta}-catenin/HRP2 axis, allowing potent inhibition of cancer cell survival, stemness and metastasis in metastatic and drug-resistant ovarian cancer cells. Promising results were also obtained in clinically relevant patient-derived ascites and organoids, alongside high tumor-oriented accumulation and favorable pharmacokinetic properties in mouse models. Furthermore, Bola/IM displayed synergistic anticancer activity when combined with the first-line chemotherapeutic drug cisplatin in patient-derived xenograft mouse models, without any adverse effects. Our findings support the use of Bola/IM as a nanoformulation to empower IM, providing targeted and potent treatment of metastatic ovarian cancer. Our study thus represents a significant advancement towards addressing the unmet medical need for improved therapies targeting this challenging disease.

cancer biology↗